☰

Hsu-Ping Kuo, Ph.D. - Publications

Affiliations: 
2009 The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Molecular Biology
Tree Info Similar researchers PubMed Report error

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Kuo HP, Ezell SA, Schweighofer KJ, Cheung LW, Hsieh S, Apatira M, Sirisawad M, Eckert K, Hsu SJ, Chen CT, Beaupre DM, Versele M, Chang BY. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Molecular Cancer Therapeutics. PMID 28428442 DOI: 10.1158/1535-7163.Mct-16-0555  0.395
2016 Kuo HP, Ezell SA, Hsieh S, Schweighofer KJ, Cheung LW, Wu S, Apatira M, Sirisawad M, Eckert K, Liang Y, Hsu J, Chen CT, Beaupre D, Chang BY. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. American Journal of Cancer Research. 6: 2489-2501. PMID 27904766 DOI: 10.1182/Blood.V126.23.699.699  0.432
2016 Kuo H, Hsieh S, Whang J, Huang Y, Sirisawad M, Chang BY. Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas Blood. 128: 4140-4140. DOI: 10.1182/Blood.V128.22.4140.4140  0.375
2016 Huang Y, Hsu J, Sirisawad M, Kuo H, Chang BY. Abstract 4860: The BTK inhibitor ibrutinib modulates T cell immunity in mouse models and in differentiated human T cells Cancer Research. 76: 4860-4860. DOI: 10.1158/1538-7445.Am2016-4860  0.371
2016 Kuo H, Hsieh S, Schweighofer KJ, Cheung LW, Apatira M, Sirisawad M, Wu S, Eckert K, Liang Y, Hsu J, Chen C, Beaupre D, Chang BY. Abstract 3072: Combination of ibrutinib and corticosteroids in B-cell non-Hodgkin lymphomas (NHL) Cancer Research. 76: 3072-3072. DOI: 10.1158/1538-7445.Am2016-3072  0.385
2015 Wong SH, Goode DL, Iwasaki M, Wei MC, Kuo HP, Zhu L, Schneidawind D, Duque-Afonso J, Weng Z, Cleary ML. The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential. Cancer Cell. PMID 26190263 DOI: 10.1016/J.Ccell.2015.06.003  0.353
2015 Cheung LW, Schweighofer KJ, Wu S, Kuo H, Eckert K, Balasubramanian S, Ricci D, Liang Y, Beaupre D, Chang BY. Mutation Impact of Targeted Genes in Diffuse Large B-Cell Lymphoma Patients Treated with Ibrutinib Blood. 126: 2642-2642. DOI: 10.1182/Blood.V126.23.2642.2642  0.319
2015 Kuo H, Hsieh S, Chang B. Abstract 2598: Synergistic effect of ibrutinib and inhibitors targeting TLR signaling in ABC subtype of diffuse large B-Cell lymphoma Cancer Research. 75: 2598-2598. DOI: 10.1158/1538-7445.Am2015-2598  0.397
2014 Du Y, Shen J, Hsu JL, Han Z, Hsu MC, Yang CC, Kuo HP, Wang YN, Yamaguchi H, Miller SA, Hung MC. Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking. Oncogene. 33: 756-70. PMID 23376851 DOI: 10.1038/onc.2013.1  0.77
2014 Kuo H, Crowley R, Xue L, Schweighofer KJ, Cheung LW, Hsieh S, Eckert K, Versele M, Chang BY. Combination of Ibrutinib and BCL-2 or SYK Inhibitors in Ibrutinib Resistant ABC-Subtype of Diffuse Large B-Cell Lymphoma Blood. 124: 505-505. DOI: 10.1182/Blood.V124.21.505.505  0.428
2013 Kuo HP, Wang Z, Lee DF, Iwasaki M, Duque-Afonso J, Wong SH, Lin CH, Figueroa ME, Su J, Lemischka IR, Cleary ML. Epigenetic roles of MLL oncoproteins are dependent on NF-κB. Cancer Cell. 24: 423-37. PMID 24054986 DOI: 10.1016/J.Ccr.2013.08.019  0.754
2013 Huang TH, Huo L, Wang YN, Xia W, Wei Y, Chang SS, Chang WC, Fang YF, Chen CT, Lang JY, Tu C, Wang Y, Hsu MC, Kuo HP, Ko HW, et al. Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. Cancer Cell. 23: 796-810. PMID 23764002 DOI: 10.1016/j.ccr.2013.04.027  0.517
2012 Chen CT, Du Y, Yamaguchi H, Hsu JM, Kuo HP, Hortobagyi GN, Hung MC. Targeting the IKKβ/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Molecular Cancer Therapeutics. 11: 2212-21. PMID 22826466 DOI: 10.1158/1535-7163.MCT-12-0180  0.438
2012 Liu M, Lee DF, Chen CT, Yen CJ, Li LY, Lee HJ, Chang CJ, Chang WC, Hsu JM, Kuo HP, Xia W, Wei Y, Chiu PC, Chou CK, Du Y, et al. IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression. Molecular Cell. 45: 171-84. PMID 22196886 DOI: 10.1016/J.Molcel.2011.11.018  0.82
2011 Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, et al. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. The Journal of Clinical Investigation. 121: 4526-36. PMID 21985787 DOI: 10.1172/Jci45008  0.728
2011 Hsu JM, Chen CT, Chou CK, Kuo HP, Li LY, Lin CY, Lee HJ, Wang YN, Liu M, Liao HW, Shi B, Lai CC, Bedford MT, Tsai CH, Hung MC. Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nature Cell Biology. 13: 174-81. PMID 21258366 DOI: 10.1038/Ncb2158  0.648
2010 Kuo HP, Hung MC. Arrest-defective-1 protein (ARD1): tumor suppressor or oncoprotein? American Journal of Translational Research. 2: 56-64. PMID 20182582  0.495
2010 Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, Weihua Z, Yang JY, Yen CJ, Huang TH, Tan M, et al. ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Science Signaling. 3: ra9. PMID 20145209 DOI: 10.1126/Scisignal.2000590  0.781
2009 Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, Shen J, Chen CT, Huo L, Hsu MC, Li CW, Ding Q, Liao TL, Lai CC, Lin AC, et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Molecular Cell. 36: 131-40. PMID 19818716 DOI: 10.1016/J.Molcel.2009.07.025  0.801
2009 Kuo HP, Lee DF, Xia W, Wei Y, Hung MC. TNFalpha induces HIF-1alpha expression through activation of IKKbeta. Biochemical and Biophysical Research Communications. 389: 640-4. PMID 19766100 DOI: 10.1016/j.bbrc.2009.09.042  0.749
2009 Kuo HP, Lee DF, Xia W, Lai CC, Li LY, Hung MC. Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation. Biochemical and Biophysical Research Communications. 389: 156-61. PMID 19716809 DOI: 10.1016/j.bbrc.2009.08.127  0.796
2009 Chou CK, Lee DF, Sun HL, Li LY, Lin CY, Huang WC, Hsu JM, Kuo HP, Yamaguchi H, Wang YN, Liu M, Wu HY, Liao PC, Yen CJ, Hung MC. The suppression of MAD1 by AKT-mediated phosphorylation activates MAD1 target genes transcription. Molecular Carcinogenesis. 48: 1048-58. PMID 19526459 DOI: 10.1002/Mc.20557  0.798
2008 Lee DF, Kuo HP, Chen CT, Wei Y, Chou CK, Hung JY, Yen CJ, Hung MC. IKKbeta suppression of TSC1 function links the mTOR pathway with insulin resistance. International Journal of Molecular Medicine. 22: 633-8. PMID 18949383 DOI: 10.3892/ijmm_00000065  0.771
2008 Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Research. 68: 6109-17. PMID 18676833 DOI: 10.1158/0008-5472.CAN-08-0579  0.79
2008 Yen CJ, Izzo JG, Lee DF, Guha S, Wei Y, Wu TT, Chen CT, Kuo HP, Hsu JM, Sun HL, Chou CK, Buttar NS, Wang KK, Huang P, Ajani J, et al. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Research. 68: 2632-40. PMID 18413730 DOI: 10.1158/0008-5472.Can-07-5460  0.794
2008 Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nature Cell Biology. 10: 138-48. PMID 18204439 DOI: 10.1038/Ncb1676  0.757
2007 Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell. 130: 440-55. PMID 17693255 DOI: 10.1016/j.cell.2007.05.058  0.783
2007 Xie X, Xia W, Li Z, Kuo HP, Liu Y, Li Z, Ding Q, Zhang S, Spohn B, Yang Y, Wei Y, Lang JY, Evans DB, Chiao PJ, Abbruzzese JL, et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell. 12: 52-65. PMID 17613436 DOI: 10.1016/J.Ccr.2007.05.009  0.45
2006 Day CP, Rau KM, Qiu L, Liu CW, Kuo HP, Xie X, Lopez-Berestein G, Hortobagyi GN, Hung MC. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Therapy. 13: 706-19. PMID 16514421 DOI: 10.1038/sj.cgt.7700945  0.722
2004 Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Therapy. 11: 740-7. PMID 15359286 DOI: 10.1038/sj.cgt.7700752  0.487
2003 Li YM, Wen Y, Zhou BP, Kuo HP, Ding Q, Hung MC. Enhancement of Bik antitumor effect by Bik mutants. Cancer Research. 63: 7630-3. PMID 14633680  0.696
Show low-probability matches.